These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19333882)

  • 1. 'Muscle-sparing' statins: preclinical profiles and future clinical use.
    Pfefferkorn JA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):245-52. PubMed ID: 19333882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
    Pfefferkorn JA; Choi C; Larsen SD; Auerbach B; Hutchings R; Park W; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C; Harris MS; Pavlovsky A; Bainbridge G; Caspers N; Kowala M; Tait BD
    J Med Chem; 2008 Jan; 51(1):31-45. PubMed ID: 18072721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin therapy in the elderly: a review.
    Szadkowska I; Stanczyk A; Aronow WS; Kowalski J; Pawlicki L; Ahmed A; Banach M
    Arch Gerontol Geriatr; 2010; 50(1):114-8. PubMed ID: 19217673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic determinants of atorvastatin response.
    Rodrigues AC; Hirata MH; Hirata RD
    Curr Opin Mol Ther; 2007 Dec; 9(6):545-53. PubMed ID: 18041665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?
    Gupta S
    Int J Cardiol; 2004 Aug; 96(2):131-9. PubMed ID: 15262025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
    Pfefferkorn JA
    Expert Opin Ther Pat; 2011 Feb; 21(2):187-203. PubMed ID: 21214503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 9. Current overview of statin-induced myopathy.
    Rosenson RS
    Am J Med; 2004 Mar; 116(6):408-16. PubMed ID: 15006590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
    Whayne TF
    Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Langmann T
    Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of aggressive statin therapy.
    Conn Med; 2005; 69(6):339-41. PubMed ID: 16184860
    [No Abstract]   [Full Text] [Related]  

  • 14. Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
    Rodríguez C; Alcudia JF; Martínez-González J; Guadall A; Raposo B; Sánchez-Gómez S; Badimon L
    Cardiovasc Res; 2009 Aug; 83(3):595-603. PubMed ID: 19406911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose statin therapy: benefits and safety in aggressive lipid lowering.
    Toth PP; Davidson MH
    J Fam Pract; 2008 May; 57(5 Suppl High-Dose):S29-36. PubMed ID: 18662521
    [No Abstract]   [Full Text] [Related]  

  • 16. The past, present, and future of statin therapy.
    Watson KE; Fonarow GC
    Rev Cardiovasc Med; 2005; 6(3):129-39. PubMed ID: 16195686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ; Rawal B; Khan NA; Yeramaneni S; Goldenberg N; Wang P
    Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.
    Pfefferkorn JA; Litchfield J; Hutchings R; Cheng XM; Larsen SD; Auerbach B; Bush MR; Lee C; Erasga N; Bowles DM; Boyles DC; Lu G; Sekerke C; Askew V; Hanselman JC; Dillon L; Lin Z; Robertson A; Olsen K; Boustany C; Atkinson K; Goosen TC; Sahasrabudhe V; Chupka J; Duignan DB; Feng B; Scialis R; Kimoto E; Bi YA; Lai Y; El-Kattan A; Bakker-Arkema R; Barclay P; Kindt E; Le V; Mandema JW; Milad M; Tait BD; Kennedy R; Trivedi BK; Kowala M
    Bioorg Med Chem Lett; 2011 May; 21(9):2725-31. PubMed ID: 21183342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP; Peng DQ; Yu BL; Huo Y;
    Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
    Park WK; Kennedy RM; Larsen SD; Miller S; Roth BD; Song Y; Steinbaugh BA; Sun K; Tait BD; Kowala MC; Trivedi BK; Auerbach B; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1151-6. PubMed ID: 18155906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.